



# COLOPLAST A/S SER. B

ISIN: DK0060448595 WKN: - Asset Class: **Stock**

|  |   |
|--|---|
| <b>Company</b>   | 2024/04/25 16:59:42   |
|  | <b>Price</b><br><b>864.20</b><br>DKK  |
|  | <b>Difference</b>  <b>-6.27%(-57.80)</b> |



|                        |  |
|------------------------|--|
| <b>Contact Details</b> |  |
| COLOPLAST A/S          | Tel: +45-49-11-11-11   |
| --                     | Fax: +   |
| Holtedam 1-3           | Web: <a href="http://www.coloplast.com">http://www.coloplast.com</a> |
| 3050 Humlebaek         | E-mail: -  |

## Company Profile

Coloplast A/S engages in the developing, manufacture, and markets medical products. It operates through the following segments: Chronic Care, Voice and Respiratory Care, Interventional Urology, Advanced Wound Dressings, and Biologics. The Chronic Care segment covers the sale of ostomy care products and continence care products. The Voice and Respiratory Care segment refers to the sale of laryngectomy and tracheostomy products. The Interventional Urology segment includes the sale of urological products, including disposable products. The Advanced Wound Dressings segment focuses on the sale of wound and skin care products. The Biologics segment represents a new segment covering the sale of tissue-based products. The company was founded by Aage Louis-Hansen and Johanne Louise-Hansen in 1954 and is headquartered in Humlebaek, Denmark.

## Financial figures, Fiscal year: from 01.10. to 30.09.

| Financial figures                     | 2023           |                        | 2022           |                        | 2021           |                        |
|---------------------------------------|----------------|------------------------|----------------|------------------------|----------------|------------------------|
|                                       | Assets         | Liabilities and equity | Assets         | Liabilities and equity | Assets         | Liabilities and equity |
| <b>Current assets</b>                 | 9,937,000,000  |                        | 8,772,000,000  |                        | 6,994,000,000  |                        |
| <b>Common stock capital</b>           |                | 228,000,000            |                | 216,000,000            |                | 216,000,000            |
| <b>Fixed assets</b>                   | 38,222,000,000 |                        | 26,184,000,000 |                        | 8,847,000,000  |                        |
| <b>Equity capital of a company</b>    |                | 17,299,000,000         |                | 8,292,000,000          |                | 8,168,000,000          |
| <b>Cash and cash equivalents</b>      | 911,000,000    |                        | 414,000,000    |                        | 448,000,000    |                        |
| <b>Accrued liabilities</b>            |                | 195,000,000            |                | 373,000,000            |                | 237,000,000            |
| <b>Other assets</b>                   | -              |                        | -              |                        | -              |                        |
| <b>Current liabilities</b>            |                | 16,311,000,000         |                | 7,336,000,000          |                | 6,314,000,000          |
| <b>Prepayments and accrued income</b> | -              |                        | -              |                        | -              |                        |
| <b>Non-current liabilities</b>        |                | 14,549,000,000         |                | 19,328,000,000         |                | 1,359,000,000          |
| <b>Different income</b>               |                | -                      |                | -                      |                | -                      |
| <b>Other liabilities</b>              |                | 10,000,000             |                | 23,000,000             |                | 2,000,000              |
| <b>Total assets</b>                   | 48,159,000,000 | 48,159,000,000         | 34,956,000,000 | 34,956,000,000         | 15,841,000,000 | 15,841,000,000         |

## Balance notes

|                            | 2023    | 2022    | 2021   |
|----------------------------|---------|---------|--------|
| <b>Accounting standard</b> | IFRS    | IFRS    | IFRS   |
| <b>Employees</b>           | 15,692  | 14,572  | 12,874 |
| <b>Equity ratio</b>        | 35.92%  | 23.72%  | 51.56% |
| <b>Debt-equity ratio</b>   | 178.39% | 321.56% | 93.94% |

## Others

|                         | 2023   | 2022   | 2021   |
|-------------------------|--------|--------|--------|
| <b>Tax Expense Rate</b> | 20.61% | 23.19% | 22.59% |

# COLOPLAST A/S SER. B

ISIN: DK0060448595 WKN: - Asset Class: Stock

## Income statement

|  | 2023           | 2022           | 2021           |
|--|----------------|----------------|----------------|
| <b>Turnover</b>  | 24,500,000,000 | 22,579,000,000 | 19,426,000,000 |
| <b>Net income</b>  | 4,783,000,000  | 4,706,000,000  | 4,825,000,000  |
| <b>EBIT</b>  | 888,822,000    | 847,952,000    | 841,386,000    |
| <b>Operating income before taxes</b>                                 | 6,025,000,000  | 6,127,000,000  | 6,233,000,000  |
| <b>Cash Flow</b>   | 4,226,000,000  | 5,099,000,000  | 5,290,000,000  |
| <b>Net interest income</b>   | -608,000,000   | -201,000,000   | -46,000,000    |
| <b>Research and development expenses</b>                             | 828,000,000    | 816,000,000    | 711,000,000    |
| <b>Income taxes</b>  | 1,242,000,000  | 1,421,000,000  | 1,408,000,000  |
| <b>Result from investments in subsidiaries, associates and other</b> | 0              | 0              | 0              |
| <b>Revenues per employee</b>   | 209,215        | 207,630        | 202,197        |

## Board of Directors

|                          |                               |
|--------------------------|-------------------------------|
| Lars Søren Rasmussen     | Chairman of Supervisory Board |
| Annette Brüls            | Member of Supervisory Board   |
| Carsten Hellmann         | Member of Supervisory Board   |
| Jette Nygaard-Andersen   | Member of Supervisory Board   |
| Marianne Wiinholt        | Member of Supervisory Board   |
| Niels Peter Louis-Hansen | Member of Supervisory Board   |
| Nikolaj Kyhe Gundersen   | Member of Supervisory Board   |
| Roland Vendelbo Pedersen | Member of Supervisory Board   |
| Thomas Barfod            | Member of Supervisory Board   |

## Members of Management Board

|                          |                               |
|--------------------------|-------------------------------|
| Kristian Villumsen       | Chairman of Managing Board    |
| Allan Rasmussen          | Member of Executive Committee |
| Anders Lonning-Skovgaard | Member of Executive Committee |
| Dorthe Ronnau            | Member of Executive Committee |
| Nicolai Buhl Andersen    | Member of Executive Committee |
| Paul Marcun              | Member of Executive Committee |